首页 > 最新文献

Bioorganic & Medicinal Chemistry Letters最新文献

英文 中文
Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of triple-negative breast cancer. n -苄基-2-氟苯酰胺作为EGFR/HDAC3双靶点抑制剂治疗三阴性乳腺癌的发现及构效关系
IF 2.2 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-12-01 Epub Date: 2025-08-05 DOI: 10.1016/j.bmcl.2025.130362
Gong-Hui Ge, Shuai Guo, Ting-Ting Li, Yan-Ping Wang, Li-Rong Liu, Wen-Hui Yu, Hao Hu, Yi-Meng Zheng, Jing-Han Yan, Ying-Hao Sun, Jing-Wei Liang, Fan-Hao Meng, Ting-Jian Zhang

Epidermal growth factor receptor (EGFR) and histone deacetylase 3 (HDAC3) synergistically drive malignant progression in triple-negative breast cancer (TNBC). In this study, a series of N-benzyl-2-fluorobenzamide derivatives (11-43) were identified as EGFR/HDAC3 dual-target inhibitors. Among them, compound 38 exhibited the most promising activity, with IC₅₀ values of 20.34 nM and 1.09 μM against EGFR and HDAC3, respectively. Molecular modeling revealed that the 2-fluorobenzamide moiety of 38 chelates with Zn2+ in the active channel of HDAC3, while the 4-fluorobenzyl group occupies the ATP-binding pocket of EGFR, exercising a dual-target binding function. In vitro experiments demonstrated that 38 exhibited superior anti-proliferative activity (IC₅₀ = 1.98 μM) against MDA-MB-231 cells compared to chidamide (IC₅₀ = 24.37 μM), inducing 74.15 % inhibition of cell migration and 57.4 % late-stage apoptosis. In vivo studies revealed that 38 (30 mg/kg/day) suppressed tumor growth by 34.78 % without significant toxicity. Collectively, 38 represents a novel dual EGFR/HDAC3 inhibitor that shows promising potential for providing new therapeutic insights into TNBC treatment.

表皮生长因子受体(EGFR)和组蛋白去乙酰化酶3 (HDAC3)协同推动三阴性乳腺癌(TNBC)的恶性进展。本研究鉴定了一系列n -苄基-2-氟苯甲酰胺衍生物(11-43)为EGFR/HDAC3双靶点抑制剂。其中,化合物38表现出最有希望的活性,对EGFR和HDAC3的IC₅₀值分别为20.34 nM和1.09 μM。分子模型显示,38个分子的2-氟苯甲酰胺部分与Zn2+在HDAC3的活性通道中螯合,而4-氟苯基占据EGFR的atp结合口袋,具有双靶标结合功能。体外实验表明,与奇达酰胺(IC₅₀ = 24.37 μM)相比,38对MDA-MB-231细胞具有优越的抗增殖活性(IC₅₀ = 1.98 μM),诱导74.15% %的细胞迁移抑制和57.4% %的晚期凋亡。体内研究显示,38(30 mg/kg/天)抑制肿瘤生长34.78 %,无明显毒性。总的来说,38代表了一种新的双重EGFR/HDAC3抑制剂,显示出为TNBC治疗提供新的治疗见解的潜力。
{"title":"Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of triple-negative breast cancer.","authors":"Gong-Hui Ge, Shuai Guo, Ting-Ting Li, Yan-Ping Wang, Li-Rong Liu, Wen-Hui Yu, Hao Hu, Yi-Meng Zheng, Jing-Han Yan, Ying-Hao Sun, Jing-Wei Liang, Fan-Hao Meng, Ting-Jian Zhang","doi":"10.1016/j.bmcl.2025.130362","DOIUrl":"10.1016/j.bmcl.2025.130362","url":null,"abstract":"<p><p>Epidermal growth factor receptor (EGFR) and histone deacetylase 3 (HDAC3) synergistically drive malignant progression in triple-negative breast cancer (TNBC). In this study, a series of N-benzyl-2-fluorobenzamide derivatives (11-43) were identified as EGFR/HDAC3 dual-target inhibitors. Among them, compound 38 exhibited the most promising activity, with IC₅₀ values of 20.34 nM and 1.09 μM against EGFR and HDAC3, respectively. Molecular modeling revealed that the 2-fluorobenzamide moiety of 38 chelates with Zn<sup>2+</sup> in the active channel of HDAC3, while the 4-fluorobenzyl group occupies the ATP-binding pocket of EGFR, exercising a dual-target binding function. In vitro experiments demonstrated that 38 exhibited superior anti-proliferative activity (IC₅₀ = 1.98 μM) against MDA-MB-231 cells compared to chidamide (IC₅₀ = 24.37 μM), inducing 74.15 % inhibition of cell migration and 57.4 % late-stage apoptosis. In vivo studies revealed that 38 (30 mg/kg/day) suppressed tumor growth by 34.78 % without significant toxicity. Collectively, 38 represents a novel dual EGFR/HDAC3 inhibitor that shows promising potential for providing new therapeutic insights into TNBC treatment.</p>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":" ","pages":"130362"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144787866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Synthesis of pisiferic acid analogues and their anti-adipogenic effect in 3T3-L1 adipocytes. 三烯二酸类似物的合成及其对3T3-L1脂肪细胞的抗脂肪生成作用。
IF 2.2 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-12-01 Epub Date: 2025-08-07 DOI: 10.1016/j.bmcl.2025.130354
Ayako Oshika, Sayumi Ono, Haruka Iwano, Manami Toda, Risa Obayashi, Yuna Takagi, Mako Higashitani, Satomi Fukuoka, Miduki Furukawa, Karen Yagami, Rena Okamura, Natsumi Futoi, Hiroki Yoshioka, Reiko Yano, Koji Yoshida, Hyun-Sun Park, Tomoyo Hasuda, Yukio Hitotsuyanagi, Koichi Takeya, Tomohiro Yamaguchi, Yutaka Aoyagi

12-O-alkyl, acyl, and phenylcarbamoyl, and 11-bromo-7-oxo analogues were prepared from pisiferic acid from Chamaecyparis pisifera, and evaluated anti-adipogenic activity. Among them, pisiferic acid and methyl 12-O-phenylcarbamoylpisiferic acid methyl ester showed relatively high anti-adipogenic effect in 3T3-L1 adipocytes and should be thought to be potential candidates for anti-obesity drug.

以松香豆酸为原料制备了12- o-烷基、酰基、苯基氨基甲酰和11-溴-7-氧类似物,并对其抗脂肪活性进行了评价。其中,pisiferic酸和甲基12- o -苯基氨基甲酰pisiferic酸甲酯在3T3-L1脂肪细胞中表现出较高的抗脂肪作用,应被认为是抗肥胖药物的潜在候选者。
{"title":"Synthesis of pisiferic acid analogues and their anti-adipogenic effect in 3T3-L1 adipocytes.","authors":"Ayako Oshika, Sayumi Ono, Haruka Iwano, Manami Toda, Risa Obayashi, Yuna Takagi, Mako Higashitani, Satomi Fukuoka, Miduki Furukawa, Karen Yagami, Rena Okamura, Natsumi Futoi, Hiroki Yoshioka, Reiko Yano, Koji Yoshida, Hyun-Sun Park, Tomoyo Hasuda, Yukio Hitotsuyanagi, Koichi Takeya, Tomohiro Yamaguchi, Yutaka Aoyagi","doi":"10.1016/j.bmcl.2025.130354","DOIUrl":"10.1016/j.bmcl.2025.130354","url":null,"abstract":"<p><p>12-O-alkyl, acyl, and phenylcarbamoyl, and 11-bromo-7-oxo analogues were prepared from pisiferic acid from Chamaecyparis pisifera, and evaluated anti-adipogenic activity. Among them, pisiferic acid and methyl 12-O-phenylcarbamoylpisiferic acid methyl ester showed relatively high anti-adipogenic effect in 3T3-L1 adipocytes and should be thought to be potential candidates for anti-obesity drug.</p>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":" ","pages":"130354"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144793047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficient synthesis, stability-guided optimization and anti-ulcerative colitis evaluation of bee venom peptide melittin. 蜂毒肽蜂毒素的高效合成、稳定性优化及抗溃疡性结肠炎评价。
IF 2.2 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-12-01 Epub Date: 2025-08-07 DOI: 10.1016/j.bmcl.2025.130357
Cheng-Jian Pang, Jing-Fang Yao, Qiu-Lan Lv, Li-Ze Zhang, Qian-Yao Yu, Li Zeng, Yun-Kun Qi

Ulcerative colitis (UC) is considered as one of the most prevalent inflammatory bowel diseases (IBDs), which increases risks for colectomy and colorectal cancer. However, due to moderate efficiency and potential side effects of first-line drugs, it is desirable to develop more efficient anti-UC agents. The natural peptide Melittin, which is the main active ingredient of bee venom, is considered as a potential scaffold for the development of anti-UC drugs. Nevertheless, as a linear amphipathic peptide, Melittin could be degraded by various proteases, suffering from poor stability and short half-lives. Previous studies on structural optimization or the potential of Melittin-derived peptides for anti-UC applications still remain limited. In this study, the stability-guided optimization and anti-UC evaluation were conducted on Melittin. The robust synthetic strategy, in vivo anti-UC activity, and anti-inflammatory mechanism were investigated. Compared with Melittin, the derived peptides represented by PCJ-675 were found to exhibit improved proteolytic stability. In the dextran sulfate sodium (DSS)-induced UC mice model, PCJ-675 could significantly alleviate both colon shortening and suppress inflammation symptoms in colon tissue. The western blotting and biochemical indicators suggested that the oral administration of PCJ-675 could protect the colon in colitis mice by inhibiting both the excessive activation of the inflammation-related TLR4/NF-κB pathway and the overexpression of pro-inflammatory cytokines (eg, IL-1β, IL-6, and TNF-α). Collectively, this study not only stablished robust strategies to improve the stability and anti-UC potential of Melittin, but also provided valuable references for the future development of natural cytotoxic peptides based anti-UC agents.

溃疡性结肠炎(UC)被认为是最常见的炎症性肠病(IBDs)之一,它增加了结肠切除术和结直肠癌的风险。然而,由于一线药物的疗效一般和潜在的副作用,需要开发更有效的抗uc药物。蜂毒的主要活性成分是天然多肽蜂毒素,被认为是开发抗uc药物的潜在支架。然而,作为一种线性两亲肽,Melittin可被多种蛋白酶降解,稳定性差,半衰期短。先前关于蜂毒肽衍生肽的结构优化或抗uc应用潜力的研究仍然有限。本研究对Melittin进行了稳定性导向优化和抗uc评价。研究了其强大的合成策略、体内抗uc活性和抗炎机制。与Melittin相比,以PCJ-675为代表的衍生肽具有更好的蛋白水解稳定性。在葡聚糖硫酸钠(dextran sulfate sodium, DSS)诱导的UC小鼠模型中,PCJ-675能显著缓解结肠缩短和抑制结肠组织炎症症状。western blotting及生化指标显示,口服PCJ-675可通过抑制炎症相关的TLR4/NF-κB通路的过度激活和促炎细胞因子(如IL-1β、IL-6、TNF-α)的过度表达来保护结肠炎小鼠结肠。综上所述,本研究不仅为提高Melittin的稳定性和抗uc潜力建立了稳健的策略,也为未来开发基于天然细胞毒肽的抗uc药物提供了有价值的参考。
{"title":"Efficient synthesis, stability-guided optimization and anti-ulcerative colitis evaluation of bee venom peptide melittin.","authors":"Cheng-Jian Pang, Jing-Fang Yao, Qiu-Lan Lv, Li-Ze Zhang, Qian-Yao Yu, Li Zeng, Yun-Kun Qi","doi":"10.1016/j.bmcl.2025.130357","DOIUrl":"10.1016/j.bmcl.2025.130357","url":null,"abstract":"<p><p>Ulcerative colitis (UC) is considered as one of the most prevalent inflammatory bowel diseases (IBDs), which increases risks for colectomy and colorectal cancer. However, due to moderate efficiency and potential side effects of first-line drugs, it is desirable to develop more efficient anti-UC agents. The natural peptide Melittin, which is the main active ingredient of bee venom, is considered as a potential scaffold for the development of anti-UC drugs. Nevertheless, as a linear amphipathic peptide, Melittin could be degraded by various proteases, suffering from poor stability and short half-lives. Previous studies on structural optimization or the potential of Melittin-derived peptides for anti-UC applications still remain limited. In this study, the stability-guided optimization and anti-UC evaluation were conducted on Melittin. The robust synthetic strategy, in vivo anti-UC activity, and anti-inflammatory mechanism were investigated. Compared with Melittin, the derived peptides represented by PCJ-675 were found to exhibit improved proteolytic stability. In the dextran sulfate sodium (DSS)-induced UC mice model, PCJ-675 could significantly alleviate both colon shortening and suppress inflammation symptoms in colon tissue. The western blotting and biochemical indicators suggested that the oral administration of PCJ-675 could protect the colon in colitis mice by inhibiting both the excessive activation of the inflammation-related TLR4/NF-κB pathway and the overexpression of pro-inflammatory cytokines (eg, IL-1β, IL-6, and TNF-α). Collectively, this study not only stablished robust strategies to improve the stability and anti-UC potential of Melittin, but also provided valuable references for the future development of natural cytotoxic peptides based anti-UC agents.</p>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":" ","pages":"130357"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144783122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
11C-labeling of 20(S)-protopanaxadiol, an aglycon of ginsenoside, based on the use of Pd(0)-mediated rapid C-[11C]methylation of boronic precursors. 基于Pd(0)介导的硼前体快速C-[11C]甲基化,对20(S)-原人参二醇(人参皂苷的糖基)进行11C标记。
IF 2.2 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-12-01 Epub Date: 2025-08-05 DOI: 10.1016/j.bmcl.2025.130356
Yoshiki Ooshima, Hiroko Koyama, Aya Ogata, Hiroshi Ikenuma, Takashi Yamada, Hiroyuki Kojima, Takashi Kato, Yasuyuki Kimura, Masaaki Suzuki

Ginsenosides, the pharmacologically active components of Panax ginseng, are widely used in herbal medicine and reportedly exert diverse biological effects, including anticancer, anti-inflammatory, and neuroprotective activities. However, their pharmacological mechanisms remain poorly understood, owing to the lack of chemical probes suitable for in vivo analyses. Herein, we report the development of a 11C radiolabeling of 20(S)-protopanaxadiol (PPD), a major aglycone-type active ginsenoside metabolite, for positron emission tomography (PET) imaging. For the 11C labeling of PPD, we focused on the terminal vinyl methyl group of the dammarane-type triterpene backbone, a common structural element found in ginsenosides. A boronic precursor applicable for rapid 11C-methylation was efficiently synthesized via steps focusing on the controlled cross-metathesis of an internal olefin. The subsequent Pd(0)-mediated rapid 11C-methylation was conducted in N,N-dimethylformamide (DMF)/H₂O using [Pd₂(dba)₃], P(o-tolyl)₃, and sodium ascorbate, which functioned as a base and a radical scavenger. After formulation, the resulting [11C]PPD was obtained in a decay-corrected radiochemical yield of 15 ± 2 % (n = 3), with a total radioactivity of 1.0 ± 0.3 GBq (n = 3) and molar activity of 124 ± 7 GBq/μmol (n = 3). Radiochemical purity was ≥99 %, and the total synthesis time was 29 min. Using [11C]PPD, PET imaging of the brains of healthy rats and abdomens of healthy mice demonstrated low brain uptake and pronouncedly clear hepatobiliary excretion of radiolabeled species. These findings may provide a foundation for the general labeling of ginsenoside structures with 11C radioisotopes, thereby enabling systematic in vivo pharmacokinetic analyses of PPD derivatives to advance ginsenoside-based drug development.

人参皂苷是人参的药理活性成分,被广泛应用于草药中,据报道具有多种生物效应,包括抗癌、抗炎和神经保护活性。然而,由于缺乏适合体内分析的化学探针,它们的药理机制仍然知之甚少。在此,我们报道了一种用于正电子发射断层扫描(PET)成像的20(S)-原人参二醇(PPD)的11C放射性标记的发展,PPD是一种主要的苷基型活性人参皂苷代谢物。对于PPD的11C标记,我们重点关注了达玛烷型三萜主链末端的乙烯基甲基,这是人参皂苷中常见的结构元素。通过控制内烯烃的交叉复合,合成了一种适用于11c甲基化的硼前体。随后Pd(0)介导的快速11c甲基化在N,N-二甲基甲酰胺(DMF)/H₂O中进行,使用[Pd₂(dba)₃],P(O - toyl)₃和抗坏血酸钠,它作为碱和自由基清除剂。配方后,生成的c[11]获得了产后抑郁症在decay-corrected放射化学产量15 ±2  % (n = 3),总放射性 1.0±0.3  GBq (n = 3)和摩尔活动124年 ±7  GBq /μ摩尔(n = 3)。放射化学纯度≥99 %,总合成时间29 min。使用[11C]PPD,健康大鼠的大脑和健康小鼠的腹部PET成像显示低脑摄取和明显清除放射性标记物种的肝胆排泄。这些发现可能为用11C放射性同位素标记人参皂苷结构提供了基础,从而能够系统地分析PPD衍生物的体内药代动力学,从而推进基于人参皂苷的药物开发。
{"title":"<sup>11</sup>C-labeling of 20(S)-protopanaxadiol, an aglycon of ginsenoside, based on the use of Pd(0)-mediated rapid C-[<sup>11</sup>C]methylation of boronic precursors.","authors":"Yoshiki Ooshima, Hiroko Koyama, Aya Ogata, Hiroshi Ikenuma, Takashi Yamada, Hiroyuki Kojima, Takashi Kato, Yasuyuki Kimura, Masaaki Suzuki","doi":"10.1016/j.bmcl.2025.130356","DOIUrl":"10.1016/j.bmcl.2025.130356","url":null,"abstract":"<p><p>Ginsenosides, the pharmacologically active components of Panax ginseng, are widely used in herbal medicine and reportedly exert diverse biological effects, including anticancer, anti-inflammatory, and neuroprotective activities. However, their pharmacological mechanisms remain poorly understood, owing to the lack of chemical probes suitable for in vivo analyses. Herein, we report the development of a <sup>11</sup>C radiolabeling of 20(S)-protopanaxadiol (PPD), a major aglycone-type active ginsenoside metabolite, for positron emission tomography (PET) imaging. For the <sup>11</sup>C labeling of PPD, we focused on the terminal vinyl methyl group of the dammarane-type triterpene backbone, a common structural element found in ginsenosides. A boronic precursor applicable for rapid <sup>11</sup>C-methylation was efficiently synthesized via steps focusing on the controlled cross-metathesis of an internal olefin. The subsequent Pd(0)-mediated rapid <sup>11</sup>C-methylation was conducted in N,N-dimethylformamide (DMF)/H₂O using [Pd₂(dba)₃], P(o-tolyl)₃, and sodium ascorbate, which functioned as a base and a radical scavenger. After formulation, the resulting [<sup>11</sup>C]PPD was obtained in a decay-corrected radiochemical yield of 15 ± 2 % (n = 3), with a total radioactivity of 1.0 ± 0.3 GBq (n = 3) and molar activity of 124 ± 7 GBq/μmol (n = 3). Radiochemical purity was ≥99 %, and the total synthesis time was 29 min. Using [<sup>11</sup>C]PPD, PET imaging of the brains of healthy rats and abdomens of healthy mice demonstrated low brain uptake and pronouncedly clear hepatobiliary excretion of radiolabeled species. These findings may provide a foundation for the general labeling of ginsenoside structures with <sup>11</sup>C radioisotopes, thereby enabling systematic in vivo pharmacokinetic analyses of PPD derivatives to advance ginsenoside-based drug development.</p>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":" ","pages":"130356"},"PeriodicalIF":2.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144774419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the therapeutic potential of deuterated PPARγ agonists for NASH 探索氘化PPARγ激动剂治疗NASH的潜力。
IF 2.2 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-11-28 DOI: 10.1016/j.bmcl.2025.130489
Xudong Pang , Dawei Cui , Ruifeng Liu , Binhua Lv , Cheng-Yun Wang
NASH represents an increasingly prevalent chronic liver disease, and TZDs are investigated as a potential therapeutic strategy. However, the inherent enolic structure of TZDs leads to enantiomeric instability and racemization, often requiring their use as racemic mixtures. We here report the development of a novel TZD-derivative, 9, in which deuterium incorporation at the chiral center was strategically employed to enhance stereoisomeric stability while maintaining the desired pharmacological profile. In vitro, compound 9 displayed robust activity, with an EC50 of 0.32 ± 0.04 μM in HEK293 cells. Pharmacokinetic analysis revealed a Cmax of 1693 ± 339 ng/mL and an AUC0-24h of 8711 ± 871 ng∙h/mL. Furthermore, compound 9 demonstrated superior therapeutic efficacy in a mouse model of NASH. These findings suggest that the compound 9 represents a promising therapeutic candidate for NASH.
NASH是一种越来越普遍的慢性肝病,而TZDs作为一种潜在的治疗策略被研究。然而,tzd固有的烯醛结构导致对映体不稳定和外消旋,通常需要它们作为外消旋混合物使用。我们在此报告了一种新的tzd衍生物的开发,9,其中氘在手性中心的掺入被战略性地用于增强立体异构体的稳定性,同时保持所需的药理学特征。在体外,化合物9在HEK293细胞中的EC50值为0.32 ± 0.04 μM。药代动力学分析显示Cmax为1693 ± 339 ng/mL, AUC0-24h为8711 ± 871 ng∙h/mL。此外,化合物9在NASH小鼠模型中显示出优越的治疗效果。这些发现表明,该化合物9是一种有希望的NASH治疗候选药物。
{"title":"Exploring the therapeutic potential of deuterated PPARγ agonists for NASH","authors":"Xudong Pang ,&nbsp;Dawei Cui ,&nbsp;Ruifeng Liu ,&nbsp;Binhua Lv ,&nbsp;Cheng-Yun Wang","doi":"10.1016/j.bmcl.2025.130489","DOIUrl":"10.1016/j.bmcl.2025.130489","url":null,"abstract":"<div><div>NASH represents an increasingly prevalent chronic liver disease, and TZDs are investigated as a potential therapeutic strategy. However, the inherent enolic structure of TZDs leads to enantiomeric instability and racemization, often requiring their use as racemic mixtures. We here report the development of a novel TZD-derivative, <strong>9</strong>, in which deuterium incorporation at the chiral center was strategically employed to enhance stereoisomeric stability while maintaining the desired pharmacological profile. In vitro, compound <strong>9</strong> displayed robust activity, with an EC<sub>50</sub> of 0.32 ± 0.04 μM in HEK293 cells. Pharmacokinetic analysis revealed a C<sub>max</sub> of 1693 ± 339 ng/mL and an AUC<sub>0-24h</sub> of 8711 ± 871 ng∙h/mL. Furthermore, compound <strong>9</strong> demonstrated superior therapeutic efficacy in a mouse model of NASH. These findings suggest that the compound <strong>9</strong> represents a promising therapeutic candidate for NASH.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"132 ","pages":"Article 130489"},"PeriodicalIF":2.2,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145647004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design, synthesis, and activity evaluation of alpinetin derivatives as potential anti-liver cancer drugs 作为潜在抗肝癌药物的高血糖素衍生物的设计、合成及活性评价。
IF 2.2 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-11-27 DOI: 10.1016/j.bmcl.2025.130482
Yanhui Yi , Yupei Sun , Xiangyang Zhang , Jianzeng Xin , Feng Zhao , Wei Zhu , Sheng Liu
Liver cancer represents a major global health challenge, significantly impacting populations both in China and worldwide. Alpinetin (ALP), extracted from the ginger plant cardamom, has been shown to possess significant anti-liver cancer activity. However, its solubility and mechanism of action remain unclear, hindering its further development and application. Heat shock protein 70 (HSP70) has been proven to be a potential target for the treatment of liver cancer. Based on rational drug design principles, ALP was conjugated with specific pharmacophores through oxime linkages to yield novel compounds, aiming to reduce toxicity and enhanced activity. Thus, representative compounds 1a and 1b were obtained. Then, the preliminary mechanism of action was further investigated. Western blot analysis results indicate that compounds 1a and 1b could inhibit the expression of HSP70 protein in HepG2 liver cancer cells. Cell apoptosis data indicate that the synthesized compounds exert anticancer activity by inducing apoptosis. Therefore, this study suggests that ALP and its derivatives may become promising drugs for exerting anti liver cancer effects by regulating the expression of HSP70 protein.
肝癌是一项重大的全球健康挑战,严重影响着中国和世界各地的人群。从生姜植物小豆蔻中提取的扁桃素(ALP)具有显著的抗肝癌活性。但其溶解度和作用机制尚不清楚,阻碍了其进一步开发和应用。热休克蛋白70 (HSP70)已被证明是治疗肝癌的潜在靶点。根据合理的药物设计原则,ALP通过肟键与特定的药物载体偶联,生成新的化合物,以降低毒性和增强活性。从而得到具有代表性的化合物1a和1b。然后,进一步探讨了其初步作用机理。Western blot分析结果表明,化合物1a和1b可抑制HepG2肝癌细胞中HSP70蛋白的表达。细胞凋亡数据表明,合成的化合物通过诱导细胞凋亡发挥抗癌作用。因此,本研究提示ALP及其衍生物可能通过调控HSP70蛋白的表达而成为发挥抗肝癌作用的有前景的药物。
{"title":"Design, synthesis, and activity evaluation of alpinetin derivatives as potential anti-liver cancer drugs","authors":"Yanhui Yi ,&nbsp;Yupei Sun ,&nbsp;Xiangyang Zhang ,&nbsp;Jianzeng Xin ,&nbsp;Feng Zhao ,&nbsp;Wei Zhu ,&nbsp;Sheng Liu","doi":"10.1016/j.bmcl.2025.130482","DOIUrl":"10.1016/j.bmcl.2025.130482","url":null,"abstract":"<div><div>Liver cancer represents a major global health challenge, significantly impacting populations both in China and worldwide. Alpinetin (ALP), extracted from the ginger plant cardamom, has been shown to possess significant anti-liver cancer activity. However, its solubility and mechanism of action remain unclear, hindering its further development and application. Heat shock protein 70 (HSP70) has been proven to be a potential target for the treatment of liver cancer. Based on rational drug design principles, ALP was conjugated with specific pharmacophores through oxime linkages to yield novel compounds, aiming to reduce toxicity and enhanced activity. Thus, representative compounds 1a and 1b were obtained. Then, the preliminary mechanism of action was further investigated. Western blot analysis results indicate that compounds 1a and 1b could inhibit the expression of HSP70 protein in HepG2 liver cancer cells. Cell apoptosis data indicate that the synthesized compounds exert anticancer activity by inducing apoptosis. Therefore, this study suggests that ALP and its derivatives may become promising drugs for exerting anti liver cancer effects by regulating the expression of HSP70 protein.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"132 ","pages":"Article 130482"},"PeriodicalIF":2.2,"publicationDate":"2025-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145627313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iridium and rhenium complexes in photodynamic and sonodynamic therapy: mechanistic insights and therapeutic potential 光动力和声动力治疗中的铱和铼配合物:机理见解和治疗潜力。
IF 2.2 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-11-24 DOI: 10.1016/j.bmcl.2025.130479
Sreejani Ghosh , Rinku Chakrabarty , Priyankar Paira
Cancer maintains to be a major worldwide health epidemic, and despite breakthroughs in targeted agents, immunotherapy, chemotherapy, and surgery, considerable limitations persist. These comprise therapeutic resistance, dose-limiting toxicities, late diagnosis, and microenvironmental barriers, including hypoxia and poor perfusion. The spatiotemporally regulated, locally activated cytotoxicity that photodynamic therapy (PDT) and sonodynamic therapy (SDT) provide has made them appealing substitutes. They may also be used in conjunction with immunotherapy and imaging. SDT uses ultrasound to allow for deeper penetration and partial oxygen independence, whereas PDT uses light to activate photosensitisers. Both approaches produce radical intermediates and reactive oxygen species (ROS), which harm vital biomolecules and activate several pathways leading to programmed cell death, hence decreasing the probability of resistance. However, SDT necessitates the optimisation of acoustic parameters and verified clinical protocols, while PDT is limited by oxygen reliance and poor light penetration. Transition metal complexes, especially those of iridium (III) and rhenium (I), offer special benefits for PDT and SDT because of their intrinsic luminescence, effective triplet-state creation, high spin–orbit coupling, and variable photophysical characteristics. Their translational potential is being advanced by rational design tactics such as theranostic pairing, red/NIR and two-photon activation, nanocarrier integration, and Type I biasing for hypoxia tolerance. With continuous attempts to standardise dosimetry and sensitiser design, SDT is still in the early phases of evaluation, whereas PDT is clinically established. This study highlights Ir and Re complexes as adaptable next-generation sensitisers that could broaden the therapeutic reach of externally activated cancer medicines by synthesising molecular insights, representative chemical classes, and translational obstacles.
癌症仍然是世界范围内主要的健康流行病,尽管在靶向药物、免疫疗法、化疗和手术方面取得了突破,但仍存在相当大的局限性。这些障碍包括治疗耐药性、剂量限制性毒性、晚期诊断和微环境障碍,包括缺氧和灌注不良。光动力疗法(PDT)和声动力疗法(SDT)提供的时空调节、局部激活的细胞毒性使它们成为有吸引力的替代品。它们也可以与免疫疗法和成像结合使用。SDT使用超声波允许更深的穿透和部分氧不依赖性,而PDT使用光来激活光敏剂。这两种方法都会产生自由基中间体和活性氧(ROS),它们会损害重要的生物分子,并激活几种导致程序性细胞死亡的途径,从而降低耐药性的可能性。然而,SDT需要优化声学参数和经过验证的临床方案,而PDT则受氧气依赖和光线穿透性差的限制。过渡金属配合物,特别是铱(III)和铼(I)的配合物,由于其固有的发光,有效的三重态产生,高自旋轨道耦合和可变的光物理特性,为PDT和SDT提供了特殊的好处。通过合理的设计策略,如治疗配对、红/近红外和双光子激活、纳米载流子集成和I型耐缺氧偏置,它们的转化潜力正在提高。随着对剂量学和致敏剂设计标准化的不断尝试,SDT仍处于评估的早期阶段,而PDT已在临床建立。这项研究强调了Ir和Re复合物作为适应性强的下一代增敏剂,可以通过合成分子见解,代表性化学类别和翻译障碍来扩大外部激活癌症药物的治疗范围。
{"title":"Iridium and rhenium complexes in photodynamic and sonodynamic therapy: mechanistic insights and therapeutic potential","authors":"Sreejani Ghosh ,&nbsp;Rinku Chakrabarty ,&nbsp;Priyankar Paira","doi":"10.1016/j.bmcl.2025.130479","DOIUrl":"10.1016/j.bmcl.2025.130479","url":null,"abstract":"<div><div>Cancer maintains to be a major worldwide health epidemic, and despite breakthroughs in targeted agents, immunotherapy, chemotherapy, and surgery, considerable limitations persist. These comprise therapeutic resistance, dose-limiting toxicities, late diagnosis, and microenvironmental barriers, including hypoxia and poor perfusion. The spatiotemporally regulated, locally activated cytotoxicity that photodynamic therapy (PDT) and sonodynamic therapy (SDT) provide has made them appealing substitutes. They may also be used in conjunction with immunotherapy and imaging. SDT uses ultrasound to allow for deeper penetration and partial oxygen independence, whereas PDT uses light to activate photosensitisers. Both approaches produce radical intermediates and reactive oxygen species (ROS), which harm vital biomolecules and activate several pathways leading to programmed cell death, hence decreasing the probability of resistance. However, SDT necessitates the optimisation of acoustic parameters and verified clinical protocols, while PDT is limited by oxygen reliance and poor light penetration. Transition metal complexes, especially those of iridium (III) and rhenium (I), offer special benefits for PDT and SDT because of their intrinsic luminescence, effective triplet-state creation, high spin–orbit coupling, and variable photophysical characteristics. Their translational potential is being advanced by rational design tactics such as theranostic pairing, red/NIR and two-photon activation, nanocarrier integration, and Type I biasing for hypoxia tolerance. With continuous attempts to standardise dosimetry and sensitiser design, SDT is still in the early phases of evaluation, whereas PDT is clinically established. This study highlights Ir and Re complexes as adaptable next-generation sensitisers that could broaden the therapeutic reach of externally activated cancer medicines by synthesising molecular insights, representative chemical classes, and translational obstacles.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"132 ","pages":"Article 130479"},"PeriodicalIF":2.2,"publicationDate":"2025-11-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145627295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
LXH254 hybrid with adamantane: synthesis and in vitro evaluation of 2,4,6-trisubstituted pyridine derivative Z-001 containing adamantyl moiety as a novel B-RAF inhibitor 金刚烷- LXH254杂化物:含金刚烷基的2,4,6-三取代吡啶衍生物Z-001的合成及体外评价
IF 2.2 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-11-21 DOI: 10.1016/j.bmcl.2025.130481
Wei Fan , Meina Li , Yeming Wang
In this study, 2,4,6-trisubstituted pyridine derivative Z-001 containing adamantyl moiety was designed through the hybridization strategy of LXH254 and adamantane. A new and effective synthetic route was established to achieve the synthesis of Z-001 through four step reactions, starting from commercially available 3-bromo-4-methylaniline and (2,6-dichloropyridin-4-yl) boronic acid. Besides, Z-001 was evaluated inhibitory activity against B-RAF kinase with IC50 value of 37.80 nM by ADP-Glo kinase assay, and it was found that Z-001 was a more potent B-RAF inhibitor than Vemurafinib (IC50 = 78.52 nM). Furthermore, molecular docking simulations showed that Z-001 bound to DFG-out/C-helix-in conformation in the B-RAF kinase, and formed three hydrogen bonds with GLU501, ASP594 and CYS532, respectively. It was worth noting that the adamantane alcohol of Z-001 was very suitable for matching the cavities near the solvent exposed region, which was filled with adamantyl moiety and effectively utilized in the docking model. The binding mode between Z-001 and B-RAF kinase provided a reasonable explanation for Z-001 as a potential B-RAF kinase inhibitor.
本研究通过LXH254与金刚烷的杂化策略,设计了含有金刚烷片段的2,4,6-三取代吡啶衍生物Z-001。以市售的3-溴-4-甲基苯胺和(2,6-二氯吡啶-4-基)硼酸为原料,通过四步反应合成了Z-001。此外,通过ADP-Glo激酶试验评估Z-001对B-RAF激酶的抑制活性,IC50值为37.80 nM,发现Z-001比Vemurafinib更有效(IC50 = 78.52 nM)。此外,分子对接模拟表明,Z-001在B-RAF激酶中结合到DFG-out/ c -螺旋-in构象,并分别与GLU501、ASP594和CYS532形成3个氢键。值得注意的是,Z-001的金刚烷醇非常适合匹配溶剂暴露区附近的空腔,其中充满金刚烷基部分,在对接模型中得到了有效的利用。Z-001与B-RAF激酶的结合模式为Z-001作为潜在的B-RAF激酶抑制剂提供了合理的解释。
{"title":"LXH254 hybrid with adamantane: synthesis and in vitro evaluation of 2,4,6-trisubstituted pyridine derivative Z-001 containing adamantyl moiety as a novel B-RAF inhibitor","authors":"Wei Fan ,&nbsp;Meina Li ,&nbsp;Yeming Wang","doi":"10.1016/j.bmcl.2025.130481","DOIUrl":"10.1016/j.bmcl.2025.130481","url":null,"abstract":"<div><div>In this study, 2,4,6-trisubstituted pyridine derivative <strong>Z-001</strong> containing adamantyl moiety was designed through the hybridization strategy of LXH254 and adamantane. A new and effective synthetic route was established to achieve the synthesis of <strong>Z-001</strong> through four step reactions, starting from commercially available 3-bromo-4-methylaniline and (2,6-dichloropyridin-4-yl) boronic acid. Besides, <strong>Z-001</strong> was evaluated inhibitory activity against B-RAF kinase with IC<sub>50</sub> value of 37.80 nM by ADP-Glo kinase assay, and it was found that <strong>Z-001</strong> was a more potent B-RAF inhibitor than Vemurafinib (IC<sub>50</sub> = 78.52 nM). Furthermore, molecular docking simulations showed that <strong>Z-001</strong> bound to DFG-out/C-helix-in conformation in the B-RAF kinase, and formed three hydrogen bonds with GLU501, ASP594 and CYS532, respectively. It was worth noting that the adamantane alcohol of <strong>Z-001</strong> was very suitable for matching the cavities near the solvent exposed region, which was filled with adamantyl moiety and effectively utilized in the docking model. The binding mode between <strong>Z-001</strong> and B-RAF kinase provided a reasonable explanation for <strong>Z-001</strong> as a potential B-RAF kinase inhibitor.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130481"},"PeriodicalIF":2.2,"publicationDate":"2025-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145585582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chemiluminescent probes for imaging cysteine cathepsin activity 半胱氨酸组织蛋白酶活性成像的化学发光探针。
IF 2.2 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-11-20 DOI: 10.1016/j.bmcl.2025.130480
Jiyun Zhu , Sara Gutkin , Shiyu Chen , Shih-Po Su , Hai Phan , Doron Shabat , Matthew Bogyo
The cysteine cathepsins are a family of proteases that are widely expressed in diverse cell types. However, because their activity is highly upregulated at sites of inflammation, they are ideal targets for imaging a range of disease pathologies including cancer, atherosclerosis, fibrosis and others. While significant advances have been made in generation of activatable ‘smart’ probes for cathepsin activity, virtually all of these agents use fluorescent reporters which require a laser light source to induce a signal from the probe. We describe here the development and application of chemiluminescent probes for imaging cysteine cathepsin activity in cells and tissues. These probes provide rapid signal generation with low background in cells and tissues without the need for a light source. We demonstrate that a cathepsin probe containing an optimal peptide sequence can be used topically to detect activity in tumor tissues, demonstrating the potential value of this approach for real-time diagnosis of cancer as well as other conditions involving inflammation.
半胱氨酸组织蛋白酶是在多种细胞类型中广泛表达的蛋白酶家族。然而,由于它们的活性在炎症部位高度上调,它们是一系列疾病病理成像的理想靶点,包括癌症、动脉粥样硬化、纤维化等。虽然在组织蛋白酶活性的可激活“智能”探针的产生方面取得了重大进展,但实际上所有这些试剂都使用荧光报告,这需要激光光源来诱导探针发出信号。我们在这里描述了化学发光探针成像细胞和组织中半胱氨酸组织蛋白酶活性的发展和应用。这些探针在细胞和组织中提供低背景的快速信号产生,而不需要光源。我们证明了包含最佳肽序列的组织蛋白酶探针可以局部用于检测肿瘤组织中的活性,证明了这种方法在实时诊断癌症以及其他涉及炎症的疾病方面的潜在价值。
{"title":"Chemiluminescent probes for imaging cysteine cathepsin activity","authors":"Jiyun Zhu ,&nbsp;Sara Gutkin ,&nbsp;Shiyu Chen ,&nbsp;Shih-Po Su ,&nbsp;Hai Phan ,&nbsp;Doron Shabat ,&nbsp;Matthew Bogyo","doi":"10.1016/j.bmcl.2025.130480","DOIUrl":"10.1016/j.bmcl.2025.130480","url":null,"abstract":"<div><div>The cysteine cathepsins are a family of proteases that are widely expressed in diverse cell types. However, because their activity is highly upregulated at sites of inflammation, they are ideal targets for imaging a range of disease pathologies including cancer, atherosclerosis, fibrosis and others. While significant advances have been made in generation of activatable ‘smart’ probes for cathepsin activity, virtually all of these agents use fluorescent reporters which require a laser light source to induce a signal from the probe. We describe here the development and application of chemiluminescent probes for imaging cysteine cathepsin activity in cells and tissues. These probes provide rapid signal generation with low background in cells and tissues without the need for a light source. We demonstrate that a cathepsin probe containing an optimal peptide sequence can be used topically to detect activity in tumor tissues, demonstrating the potential value of this approach for real-time diagnosis of cancer as well as other conditions involving inflammation.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"132 ","pages":"Article 130480"},"PeriodicalIF":2.2,"publicationDate":"2025-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145581582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Discovery of DS79540454 via fragment-based drug discovery strategy: New scaffolds of hypoxia-inducible factor prolyl hydroxylase inhibitor 基于片段的药物发现策略发现DS79540454:缺氧诱导因子脯氨酸羟化酶抑制剂的新支架。
IF 2.2 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-11-19 DOI: 10.1016/j.bmcl.2025.130476
Takeshi Fukuda, Tatsuya Nishi, Takashi Ishiyama, Ryoko Kitazawa, Ken Ishii, Shinichi Takahashi, Yuki Kawabata, Kyoji Yamaguchi, Daichi Baba, Shuichiro Ito, Naoki Tanaka
The inhibition of hypoxia-inducible factor prolyl hydroxylase domain proteins (HIF-PHDs) represents a promising strategy for treating renal anemia. We identified a hydroxypyrimidine core with HIF-PHD inhibitory activity based on a fragment-based drug discovery strategy using various X-ray crystal structures of the HIF-PHD2 domain in complex with a compound. We discovered brand-new amino succinic acid scaffolds by combining the structural information on the crystal structure complexed with 6-acetamide nicotinic acid. DS79540454 exhibits high enzyme inhibitory activity equivalent to that of DS-1093a, which has advanced to clinical trials.
抑制缺氧诱导因子脯氨酸羟化酶结构域蛋白(hif - phd)是治疗肾性贫血的一种很有前途的策略。我们基于基于片段的药物发现策略,利用HIF-PHD2结构域与化合物配合物的各种x射线晶体结构,鉴定出具有HIF-PHD抑制活性的羟基嘧啶核心。我们结合晶体结构上的结构信息,与6-乙酰胺烟酸络合,发现了全新的氨基琥珀酸支架。DS79540454具有与DS-1093a相当的高酶抑制活性,已进入临床试验阶段。
{"title":"Discovery of DS79540454 via fragment-based drug discovery strategy: New scaffolds of hypoxia-inducible factor prolyl hydroxylase inhibitor","authors":"Takeshi Fukuda,&nbsp;Tatsuya Nishi,&nbsp;Takashi Ishiyama,&nbsp;Ryoko Kitazawa,&nbsp;Ken Ishii,&nbsp;Shinichi Takahashi,&nbsp;Yuki Kawabata,&nbsp;Kyoji Yamaguchi,&nbsp;Daichi Baba,&nbsp;Shuichiro Ito,&nbsp;Naoki Tanaka","doi":"10.1016/j.bmcl.2025.130476","DOIUrl":"10.1016/j.bmcl.2025.130476","url":null,"abstract":"<div><div>The inhibition of hypoxia-inducible factor prolyl hydroxylase domain proteins (HIF-PHDs) represents a promising strategy for treating renal anemia. We identified a hydroxypyrimidine core with HIF-PHD inhibitory activity based on a fragment-based drug discovery strategy using various X-ray crystal structures of the HIF-PHD2 domain in complex with a compound. We discovered brand-new amino succinic acid scaffolds by combining the structural information on the crystal structure complexed with 6-acetamide nicotinic acid. DS79540454 exhibits high enzyme inhibitory activity equivalent to that of DS-1093a, which has advanced to clinical trials.</div></div>","PeriodicalId":256,"journal":{"name":"Bioorganic & Medicinal Chemistry Letters","volume":"131 ","pages":"Article 130476"},"PeriodicalIF":2.2,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145561929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Bioorganic & Medicinal Chemistry Letters
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1